What's Happening?
Science Corporation has received approval from Europe's medical device regulator to market its PRIMA device, a vision-restoring chip for patients with age-related macular degeneration. The device involves an outpatient procedure to implant a chip in the
eye, which works with camera-equipped glasses to restore functional vision. The company is also pursuing expedited regulatory review from the U.S. FDA for treating rare blindness conditions. Science Corp. plans to offer the device in Germany, with the first procedures expected in September. The company aims to develop a sustainable business model to support further innovations in brain-computer interfaces.
Why It's Important?
The approval of Science Corporation's PRIMA device marks a significant advancement in medical technology, offering hope to millions affected by vision loss due to age-related macular degeneration. This development highlights the potential of brain-computer interfaces in addressing complex medical conditions and improving quality of life. The company's focus on creating a sustainable business model underscores the importance of financial viability in driving innovation in the biotech sector. As Science Corp. expands its offerings, it could pave the way for further breakthroughs in medical technology and brain-computer interfaces.
